ANGN BIOM |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.99 USD | -1.21% |
|
+7.02% | -10.10% |
| 2023 | Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors | CI |
| 2023 | Angion Biomedia to Implement 10-for-1 Reverse Split | MT |
| Sales 2021 | 28.31M 2.36B | Sales 2022 | 2.3M 192M | Capitalization | 24.44M 2.04B |
|---|---|---|---|---|---|
| Net income 2021 | -54M -4.5B | Net income 2022 | -38M -3.17B | EV / Sales 2021 | 0.1 x |
| Net cash position 2021 | 84.09M 7.01B | Net cash position 2022 | 46.78M 3.9B | EV / Sales 2022 | -9.71 x |
| P/E ratio 2021 |
-1.5
x | P/E ratio 2022 |
-0.63
x | Employees | 8 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.21% | ||
| Current month | -10.10% | ||
| Current year | -10.10% |
1 year
6.50
11.20
3 years
4.60162.57
5 years
4.60263.00
10 years
4.60263.00
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 8.99 | -1.21% | 37,127 |
| 25/24/25 | 9.1 | -1.62% | 19,886 |
| 24/24/24 | 9.25 | +0.33% | 24,650 |
| 23/24/23 | 9.22 | -5.34% | 19,431 |
| 22/24/22 | 9.74 | +15.95% | 68,337 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Angion Biomedica Corp. is a clinical-stage company. The Company is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company's product candidates and programs include ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of biopharmaceutical indications, including cancer, and ANG-3777, a hepatocyte growth factor (HGF) mimetic. Its ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases.
Sector
-
- Stock Market
- Equities
- ANGN Stock
